Innovation

Pluralsight: Interview With Chief Product & Technology Officer Chris McClellen About The Online Education Company

By Amit Chowdhry ● Aug 28, 2025

Pluralsight is an online education company that provides a subscription-based platform for professional tech training and skill development. They offer a wide range of video courses, learning paths, skill assessments, and hands-on labs for individuals and businesses. Pulse 2.0 interviewed Pluralsight Chief Product & Technology Officer Chris McClellen to gain a deeper understanding of the company.

Advent To Buy Digital Point-Of-Care Network PatientPoint

By Amit Chowdhry ● Aug 28, 2025

Advent International has signed a definitive agreement to acquire PatientPoint, the largest digital point-of-care network in the U.S., from an investor group led by L Catterton and Littlejohn. The terms of the deal were not disclosed.

Maisa: $25 Million Seed Funding Raised To Scale AI Digital Work Platform

By Amit Chowdhry ● Aug 28, 2025

Maisa, a rapidly growing player in agentic AI, has secured $25 million in seed funding to accelerate the deployment of its hallucination-resistant digital workers across regulated industries. Creandum led the round with participation from Forgepoint Capital International via its joint venture with Banco Santander. Returning investors NFX and Village Global also joined, doubling down on their December 2024 pre-seed investment.

zeb: Interview With Founder & CEO Mal Vivek About The Digital Transformation Strategy Company

By Amit Chowdhry ● Aug 28, 2025

zeb is a premier digital transformation strategy company and AWS Premier Tier Partner, offering a holistic, product-centric approach that combines strategic planning with an AI-powered implementation methodology. Pulse 2.0 interviewed zeb founder and CEO Mal Vivek to gain a deeper understanding of the company.

OneChronos: Interview With CEO Kelly Littlepage About The Smart Market Platform

By Amit Chowdhry ● Aug 28, 2025

OneChronos is a U.S. equities ATS designed from the bottom up to fundamentally address the growing gap between how trading venues match orders and how traders need to execute them. Pulse 2.0 interviewed OneChronos CEO Kelly Littlepage to gain a deeper understanding of the company.

Sonara: Strategic Investment Raised For Methadone Treatment Platform

By Amit Chowdhry ● Aug 28, 2025

Sonara is a hybrid care platform designed to enhance access to and adherence to methadone treatment through a combination of in-person and virtual tools. Recently, it secured investments from new backers, including Acumen America and the Sorenson Impact Foundation, alongside its existing supporter, First Trust Capital Partners.

Vaxxas: A$90 Million Secured For Commercializing Needle-Free Vaccination Delivery Technology

By Amit Chowdhry ● Aug 28, 2025

Vaxxas, a biotechnology company developing the high-density microarray patch (HD-MAP) for needle-free vaccine delivery, has secured approximately $90 million in its latest financing round. This funding, one of the largest in Australia for a private biotech this year, consists of $49.22 million in Series D equity and $40 million in debt facilities.

BlastOne: Funding Raised From Kaltroco And Five V Capital

By Amit Chowdhry ● Aug 28, 2025

Kaltroco and Five V Capital have jointly invested in BlastOne, a leading provider of surface preparation solutions. Known for its technical capabilities and proprietary technology, BlastOne serves key markets, including infrastructure and defense, which are experiencing long-term growth and increased demand for innovative services.

Carlyle Buying intelliflo From Invesco For Up To $200 Million

By Amit Chowdhry ● Aug 28, 2025

Carlyle announced plans to buy Intelliflo from Invesco. Intelliflo makes cloud-based management software for independent financial advisors in the UK. The deal includes Intelliflo’s US subsidiaries: RedBlack, which offers portfolio rebalancing tools, and Intelliflo Portfolio, software for US financial advisors.

Incyclix Bio: $11.25 Million Series B Extension Secured For Treating Resistant Cancer

By Amit Chowdhry ● Aug 28, 2025

Incyclix Bio is a company working on advanced cancer treatments. They are developing a new drug called INX-315, a potent and selective inhibitor targeting CDK2, a protein that regulates the cell cycle. This drug aims to treat severe and resistant types of cancer.